Polycythemia vera · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Thalidomide monotherapy Variant #03 | — | R 614 268 | 540d | ~23.0 mo | — | ~2 | ~R 1 228 537 PFS proxy · indirect | 1 |
Ruxolitinib monotherapy Variant #01 | — | R 60 650 | 28d | — | — | — | — | 2 |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~39.0 mo | ~113.8 mo | ~14 | ~R 89 057 PFS proxy · indirect | 10 |
Anagrelide monotherapy Variant #01 | — | R 3 030 | 28d | — | — | — | — | — |
Hydroxyurea monotherapy Variant #01 | — | R 278 | 28d | — | ~243.6 mo | — | — | — |
Peginterferon alfa-2a monotherapy N/A - secondary systemic drug | — | R 7 | 7d | — | — | — | — | — |
Pipobroman monotherapy Variant #01 Partial | — | — | — | — | ~184.8 mo | — | — | — |
7 of 7 regimens shown